NAD+

NAD+ and its precursors are being investigated for several clinical conditions, though research remains in early stages with limited completed trials.

Cardiovascular Disease

NAD+ precursors have been studied in heart failure. One completed Phase 1/2 trial (NCT03423342) examined nicotinamide riboside supplementation in patients with systolic heart failure, though specific results from this study are not yet available in the provided evidence.

Neurodegenerative Disorders

NAD+ is being actively investigated for neurodegenerative conditions, particularly Parkinson's disease variants. The NADAPT Study (NCT06162013) is an ongoing Phase 2 randomized, double-blind trial testing NAD replenishment therapy specifically for atypical Parkinsonism. This represents one of the more advanced clinical investigations into NAD+'s therapeutic potential for neurological conditions.

The research literature suggests NAD+ may be relevant to Alzheimer's disease through metabolic pathways, with studies examining connections between NAD+ metabolism, mitochondrial function, and tau protein modifications. However, these appear to be mechanistic studies rather than completed clinical trials.

Exercise and Athletic Performance

At least one completed trial (NCT04907110) has examined NAD+ precursor supplementation in combination with exercise, though specific outcomes are not detailed in the available evidence.

Current Clinical Evidence Limitations

The clinical evidence for NAD+ supplementation remains limited. While multiple trials are listed, many have unknown status or lack published results. The mechanistic research suggests potential applications in aging, metabolic disorders, and neurodegenerative diseases, but translation to proven clinical benefits requires more robust trial data.

This information is for educational purposes only and should not be considered personalized medical advice. Consult with healthcare providers before starting any supplementation regimen.